German university spinoff Raydiax has raised €7.5 million in Series A1 funding which it plans to use to advance first‑in‑human studies of its therapy‑assistance CT (TACT) scanner and for market launch.
The round comprises €5 million in venture capital from existing investors, Bmp Ventures with IBG funds, and new investor the GETEC Family Office of Dr. Karl Gerhold, as well as €2.5 million from the European Innovation Council (EIC) Accelerator program.
The additional funding will support early clinical evaluation of TACT, development of a production‑ready system, and expansion of sales, manufacturing, and quality operations, according to Raydiax.
TACT is a dedicated CT system designed to assist in the planning, execution, and monitoring of minimally invasive cancer therapies and could enable new image‑guided cancer treatment techniques, according to the firm, a spinoff of the STIMULATE research campus at Otto von Guericke University Magdeburg.
